Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/36617
Share/Impact:
Título : Chaperone Activity of Bicyclic Nojirimycin Analogues for Gaucher Mutations in Comparison with N-(n-nonyl)Deoxynojirimycin
Autor : Luan, Zhuo, Higaki, Katsumi, Aguilar Moncayo, Matilde, Ninomiya, Haruaki, Ohno, Kousaku, García Moreno, María Isabel, Ortiz-Mellet, Carmen, García-Fernández, José Manuel, Suzuki, Yoshiyuki
Palabras clave : Gaucher disease
Glucocerebrosidase
Glucosidase
Imino sugars
Inhibitors
Medicinal chemistry
Fecha de publicación : 14-Oct-2009
Editor: Wiley-VCH
Citación : ChemBioChem 10(17): 2780-2792 (2009)
Resumen: Gaucher disease (GD), the most prevalent lysosomal storage disorder, is caused by mutations of lysosomal β-glucosidase (acid β-Glu, β-glucocerebrosidase); these mutations result in protein misfolding. Some inhibitors of this enzyme, such as the iminosugar glucomimetic N-(n-nonyl)-1-deoxynojirimycin (NN-DNJ), are known to bind to the active site and stabilize the proper folding for the catalytic form, acting as “chemical chaperones” that facilitate transport and maturation of acid β-Glu. Recently, bicyclic nojirimycin (NJ) analogues with structure of sp2 iminosugars were found to behave as very selective, competitive inhibitors of the lysosomal β-Glu. We have now evaluated the glycosidase inhibitory profile of a series of six compounds within this family, namely 5-N,6-O-(N′-octyliminomethylidene-NJ (NOI-NJ), the 6-thio and 6-amino-6-deoxy derivatives (6S-NOI-NJ and 6N-NOI-NJ) and the corresponding galactonojirimycin (GNJ) counterparts (NOI-GNJ, 6S-NOI-GNJ and 6N-NOI-GNJ), against commercial as well as lysosomal glycosidases. The chaperone effects of four selected candidates (NOI-NJ, 6S-NOI-NJ, 6N-NOI-NJ, and 6S-NOI-GNJ) were further evaluated in GD fibroblasts with various acid β-Glu mutations. The compounds showed enzyme enhancement on human fibroblasts with N188S, G202R, F213I or N370S mutations. The chaperone effects of the sp2 iminosugar were generally stronger than those observed for NN-DNJ; this suggests that these compounds are promising candidates for clinical treatment of GD patients with a broad range of β-Glu mutations, especially for neuronopathic forms of Gaucher disease.
Descripción : 13 páginas, 2 figuras, 3 tablas, 4 esquemas
Versión del editor: http://dx.doi.org/10.1002/cbic.200900442
URI : http://hdl.handle.net/10261/36617
ISSN: 1429-4227
DOI: 10.1002/cbic.200900442
Appears in Collections:(IIQ) Artículos

Files in This Item:
There are no files associated with this item.
Show full item record
 
CSIC SFX LinksSFX Query
Related articles:


Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.